Navidea receives fast-track status for new Lymphoseek indication

12/10/2013 | RTT News

The FDA has given Navidea Biopharmaceuticals fast-track status for a new indication for the company's Lymphoseek radiopharmaceutical. Navidea will submit a supplemental new drug application before the end of the year. Lymphoseek was first approved for lymphatic mapping in breast cancer and melanoma and is being considered for head and neck cancer.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY